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Abstract Human metallothioneins, small cysteine- and
metal-rich proteins, play an important role in the acquired
resistance to platinum-based anticancer drugs. These
proteins contain a M(II)4(CysS)11 cluster and a
M(II)3(CysS)9 cluster localized in the a-domain and the
b-domain, respectively. The noninducible isoform metal-
lothionein-3 (Zn7MT-3) is mainly expressed in the brain,
but was found overexpressed in a number of cancer tis-
sues. Since the structural properties of this isoform sub-
stantially differ from those of the ubiquitously occurring
Zn7MT-1/Zn7MT-2 isoforms, the reactions of cis-dia-
mminedichloridoplatinum(II) (cisplatin) and trans-dia-
mminedichloridoplatinum(II) (transplatin) with human
Zn7MT-3 were investigated and the products character-
ized. A comparison of the reaction kinetics revealed that
transplatin reacts with cysteine ligands of Zn7MT-3 faster
than cisplatin. In both binding processes, stoichiometric
amounts of Zn(II) were released from the protein. Marked
differences between the reaction rates of cisplatin and
transplatin binding to Zn7MT-3 and the formation of the
Pt–S bonds suggest that the binding of both Pt(II) com-
pounds is a complex process, involving at least two sub-
sequent binding steps. The electrospray ionization mass
spectrometry characterization of the products showed that
whereas all ligands in cisplatin were replaced by cysteine
thiolates, transplatin retained its carrier ammine ligands.
The 113Cd NMR studies of Pt1
113Cd6MT-3 revealed that
cisplatin binds preferentially to the b-domain of the pro-
tein. The rates of reaction of cisplatin and transplatin with
Zn7MT-3 were much faster than those of cisplatin and
transplatin with Zn7MT-2. The biological consequences of
a substantially higher reactivity of cisplatin toward
Zn7MT-3 than Zn7MT-2 in the acquired resistance to
platinum-based drugs are discussed.
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cis-Diamminedichloridoplatinum(II) (cisplatin) is one of
the most potent antitumor agents known, displaying clini-
cal activity against a wide variety of solid tumors, such as
ovarian, testicular, and bladder tumors. Cisplatin is also
used in combination with radiotherapy or surgical treat-
ment [1]. The cytotoxic mode of action is mediated by its
binding mainly to two adjacent purine bases of nuclear
DNA, forming primarily intrastrand cross-links. This DNA
modification distorts the DNA structure such that transla-
tion and excision repair is strongly inhibited, directing cells
into apoptosis or necrosis [2, 3].
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A geometrical isomer of cisplatin, trans-diamminedi-
chloridoplatinum(II) (transplatin), is clinically inactive.
This is believed to be due mainly to its inability to form
similar DNA adducts as cisplatin [4]. The resistance of
cancer cells to Pt(II) drugs can be either intrinsic or acquired
following Pt(II) administration [1]. The acquired resistance
after initial treatment is the major drawback of these che-
motherapeutics. Because of the strong reactivity of Pt(II)
compounds toward sulfur-donor molecules and the forma-
tion of very stable Pt–S bonds, intracellular thiols through
their competition with DNA confer resistance to antitumor
platinum drugs. The abundant intracellular thiols involved
in the drug resistance are glutathione (GSH) and metallo-
thionein (MT) [1, 5, 6]. The four MT isoforms expressed in
humans (designated MT-1 through MT-4) consist of 61–68
amino acid residues, of which 20 are conserved cysteines.
The structural studies revealed that MTs bind seven Zn(II) or
Cd(II) through cysteine thiolates forming two metal–thiolate
clusters: a M(II)3S9 cluster located in the b-domain and a
M(II)4S11 cluster in the a-domain of the protein [7]. The
ubiquitously occurring MT-1 and MT-2 isoforms are
inducible by a variety of compounds, including hormones,
cytokines, and metal ions, including Pt(II) drugs. These
proteins are involved in the zinc and copper homeostasis,
heavy metal detoxification, immune system function, and
protection from apoptosis [8–11]. Although GSH effectively
deactivates cisplatin and in the certain cancer cell lines its
cellular concentration increases upon exposure to Pt(II)
drugs, thiols of MTs react faster with cisplatin compared
with GSH [12, 13]. In cancer cells basal MT-1/MT-2
expression levels are often significantly increased, resulting
in an even stronger Pt(II) scavenging effect [14, 15]. The
overexpression of MT-1/MT-2 isoforms in response to Pt(II)
drug administration is responsible for most of the cases of
acquired resistance to cisplatin [15–17]. In our previous
studies we showed that the rates of Zn7MT-2 reaction with
cis-[Pt(N-donor)2Cl2] and trans-[Pt(N-donor)2Cl2] com-
pounds depend on the nature of the coordinated ligands and
that trans-[Pt(N-donor)2Cl2] compounds react faster. In this
reaction, owing to the high affinity of Pt(II) for cysteine
thiolates, exceeding that of Zn(II) 107 times, Zn(II) is
substituted by Pt(II) [18, 19]. The characterization of the
products showed that whereas all ligands in cis-Pt(II) com-
pounds were replaced by cysteine thiolates, trans-Pt(II)
compounds retained their nitrogen-donor ligands.
The MT-3 isoform (Zn7MT-3), also termed ‘‘neuronal
growth inhibitory factor,’’ occurs intra- and extracellularly
and shows neuroinhibitory activity in vitro that distinguishes
it from the widely expressed Zn7MT-1 and Zn7MT-2
isoforms. MT-3 shows a brain-specific expression, mainly
in glutamatergic neurons [20–23]. This isoform is unres-
ponsive to the inducers of MT-1 and MT-2 expression
mentioned above [24]. However, MT-3 was found
overexpressed in a number of cancers, such as prostatic
adenocarcinoma, esophageal cancer, and breast cancer,
where its presence positively correlates with the poor sur-
vival prognosis after platinum chemotherapy [22, 25–27].
Furthermore, since MT-3 is absent in normal bladder tissues
but is present in large amounts in bladder cancer, the use of
this isoform as a marker of this disease has been suggested
[28]. The changes in the primary structure of MT-3, which
include a unique C(6)PCP(9) motif in the b-domain and an
acidic hexapeptide insert in the a-domain (Fig. 1), translate
into widely different structural properties of Zn7MT-3
compared with Zn7MT-1/Zn7MT-2 [7, 29]. Thus, the
Zn7MT-3 structure is highly dynamic and the thiolate
ligands possess a substantially higher nucleophilicity, indi-
cated by their reactivity toward a number of compounds,
including 5,50-dithiobis(2-nitrobenzoic acid) and S-nitroso-
thiols [30–32]. However, the reactivity of Zn7MT-3 toward
cisplatin and the products formed is not known.
In the present work, the reactions of Zn7MT-3 with cis-
platin and transplatin were investigated and the products
characterized by electrospray ionization mass spectrometry
(ESI-MS) and 113Cd NMR. The studies were conducted
under nativelike conditions regarding pH, ionic strength, and
a Pt(II) to Zn7MT ratio of 2:1 relevant to in vivo studies
[18, 33]. The results obtained were compared with those
obtained with Zn7MT-2. The biological implications of these
studies for the acquired resistance to platinum-based drugs
are discussed.
Materials and methods
Expression and purification of MTs
Recombinant human MT-3 and MT-2 were expressed in
Escherichia coli as Cd(II) proteins and purified essentially
as described in [18, 34]. The correctness of the protein
Fig. 1 Alignment of amino acid sequences of human metallothionein-2 (MT-2) and metallothionein-3 (MT-3) isoforms used in this study.
Cysteine residues are highlighted in gray
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expression was verified by ESI-MS at low pH. Single mass
peaks of 6,925.7 Da (calculated 6,927.1 Da) and
6,041.0 Da (calculated 6,042.1 Da) corresponding to
metal-free MT-3 and MT-2, respectively, were obtained.
The protein purity was further assessed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis [35]. The con-
centration of reduced thiols was determined by 2,20-dithi-
odipyridine assay [36]. In all cases, a cysteine to protein
ratio of 20.0 ± 0.5 was obtained. Fully Zn(II) loaded or
Cd(II) loaded MTs were prepared by reconstitution as
described in [37]. Metal-to-protein ratios were determined
by measuring the metal content by flame atomic absorption
spectrometry (SpectrAA-110, Varian) in 15 mM HNO3
[38] and that of the protein spectrophotometrically in
0.1 M HCl (e220 = 53,000 M
-1 cm-1 for MT-3 and
48,200 M-1 cm-1 for MT-2) [36]. In all cases, a metal-to-
protein ratio of 7.0 ± 0.3 was obtained.
Platinum quantification by atomic absorption
spectrometry
Cisplatin and transplatin were purchased from Sigma (USA).
Prior to use, aqueous solutions (300–500 lM) of both
compounds were kept in the dark at room temperature for at
least 1 day and further at 4 C. The Pt(II) solutions were
freshly prepared after 1–2 months. The Pt(II) concentrations
in the stock solutions and experimental samples were
determined by flameless atomic absorption using a Varian
AA240FS fast sequential atomic absorption spectrometer
(Varian, Australia) equipped with a GTA120 graphite tube
atomizer and a PSD120 programmable sample dispenser.
Prior to analysis, the samples were diluted in15 mM HNO3.
Characterization of Pt,ZnMT species by ESI-MS
Samples of 10 lM Zn7MT-2/Zn7MT-3 or Cd7MT-2/
Cd7MT-3 were incubated in a nitrogen-purged glove box
with 2 mol equiv of cisplatin and transplatin in 10 mM N-(2-
hydroxyethyl)piperazine-N0-ethanesulfonic acid (HEPES)/
NaOH pH 7.4, 100 mM NaClO4 for 120 h. Subsequently,
unbound Pt(II) compounds were removed and the solvent
was simultaneously exchanged by passing it through a 5-mL
HiTrap desalting column (Amersham Biosciences) equili-
brated in 10 mM 4-ethylmorpholine/HOAc pH 7.0. Imme-
diately before analysis, 4 lL of the eluate was rapidly diluted
with 20 lL of 50:50:0.2 (v/v/v) CH3CN/H2O/HOAc (final
pH * 3) or 50:50 (v/v) CH3CN/H2O (final pH * 7).
ESI-MS analysis of the protein-containing solution was
performed using a Q-TOF Ultima API mass spectrometer
(Micromass, UK) essentially as described for MT-2 in our
previous work [18]. Solutions were infused through a fused
silica capillary (inner diameter 75 lm) at a flow rate of
0.5 lL min-1. Electrospray Pico Tips (inner diameter
30 lm) were obtained from New Objective (Woburn, MA,
USA). Mass spectra were acquired by scanning an m/z range
from 600 to 2,500 with a scan duration of 1 s and an interscan
delay of 0.1 s. The spray voltage was set to 2.1 kV, the cone
voltage to 50 V, the RF lens to 1, the energy to 50 V, and
collision to 15. Mass spectra were deconvoluted using the
MaxEnt 1 software program (Micromass, UK).
Kinetics of cisplatin and transplatin binding
to Zn7MT-2/Zn7MT-3
The binding of cisplatin and transplatin to Zn7MT-2 and
Zn7MT-3 was monitored by absorption spectroscopy fol-
lowing the Pt–S ligand to metal charge transfer band at
285 nm [39]. Prior to measurements, the proteins in
10 mM HEPES/NaOH pH 7.4, 100 mM NaClO4, and
water solutions of cisplatin or transplatin were rendered
oxygen-free by three freeze–pump cycles on the vacuum
line and placed into a nitrogen-purged glove box in the
dark at 4 C. An aliquot of 960 lL of the 10 lM protein
solution was quickly mixed with 40 lL of 500 lM Pt(II)
compound in a quartz cuvette and the cuvette was sealed.
The time courses of the reactions were followed spectro-
photometrically (Ultrospec 2000, Amersham Biosciences)
at 285 nm at 37 C for 120 h. The data were normalized
per Pt–S bond using e285 nm of 2,680 M
-1 cm-1 and fitted
using the Origin 7.0 software package [18].
Quantification of platinum bound to MT-3
The proteins were mixed and incubated with the Pt(II)
compounds using the conditions described for the kinetics
of platinum binding. Aliquots of 200 lL were withdrawn
after 0, 2, 5, 18, and 120 h of sample incubation. The ali-
quots were applied to Microcon YM-3 (Millipore, USA)
concentrators and the low molecular weight fraction was
separated and the concentration of unbound Pt(II) was
determined by atomic absorption. The concentration of
Pt(II) bound to the protein was calculated by subtracting
the determined Pt(II) concentration from its initial con-
centration in the sample. No evidence for the interaction of
free Pt(II) compounds or platinated MTs with Microcon
membranes was obtained in control experiments.
Kinetics of Zn(II) release from Zn7MT-3
upon Pt(II) binding
To monitor Zn(II) release from Zn7MT-2/Zn7MT-3,
experiments were carried out using the conditions descri-
bed for the Pt(II) binding to the thiolates of Zn7MT-2/
Zn7MT-3 and in the presence of 10 lL of 10 mM 2-car-
boxy-20-hydroxy-50-sulfoformazylbenzene sodium salt
(zincon), dissolved in 10 mM NaOH. The concentration of
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released Zn(II) was monitored through changes in the
absorption of the Zn(II)–zincon complex at 620 nm
(e620 nm = 23,200 M
-1 cm-1) with time [40].
113Cd NMR of Pt1
113Cd6MT-3
113Cd NMR spectra (110.9 MHz) were recorded with a
Bruker DRX-500 spectrometer using inverse-gated broad-
band proton decoupling to account for possible negative
113Cd,1H nuclear Overhauser effects. Data were sampled
over a 62,500-Hz spectral width using a 0.5-s acquisition
time and 0.3-s relaxation time. The 113Cd chemical shifts are
given in parts per million relative to external standard 0.1 M
Cd(ClO4)2. The samples were prepared in 15 mM potassium
phosphate/sodium phosphate pH 7.3, containing 10% 2H2O
for the field-frequency lock, and were measured in 5-mm
NMR tubes. The average protein concentration for 113Cd
NMR was 2.5–3 mM. The gel filtration column (Superdex
75 10/300 GL, Amersham, Sweden) was used to analyze for
a protein oligomerization after NMR measurements.
Results
Characterization of platinated MT-3 species formed
with cisplatin and transplatin
In vivo studies have shown that the administration of cis-
platin or transplatin to rabbits results in the formation of
Pt*2Zn*5MT species in liver and kidneys [33]. Therefore,
in our studies the binding of 2 mol equiv of cisplatin or
transplatin to Zn7MT-3 was investigated. Owing to the low
intracellular Cl- concentration (4–23 mM), the cis-




(X is OH-, H2O; a = 0, 1) and, to a smaller extent, cis–
[Pt(NH3)2X2]
a?/trans-[Pt(NH3)2X2]
a? (X is OH-, H2O;
a = 0, 1, 2) species [41, 42]. To mimic this situation, cis-
platin and transplatin were dissolved in H2O and allowed to
hydrolyze for at least 1 day at ambient temperature [18]. The
exchange of the leaving ligands is essential for the reaction
of Pt(II) compounds with DNA. However, no influence of
the aquation/anation degree on the reactivity of Pt(II) com-
pounds toward MTs and other thiols such as GSH or cysteine
was observed previously [43–45]. To characterize the final
products of the reaction of human Zn7MT-3 with cisplatin
and transplatin, the previously developed ESI-MS method
was used [18]. The protein was incubated with both Pt(II)
compounds for 120 h in 10 mM HEPES/NaOH, pH 7.4,
100 mM NaClO4, at 37 C. These buffer conditions were
used in all kinetic studies. To exclude cysteine oxidation by
air oxygen during the prolonged sample incubation, exper-
iments were performed under anaerobic conditions. After
incubation, the protein was transferred into 10 mM 4-eth-
ylmorpholine/HOAc, pH * 7 buffer and analyzed by ESI-
MS (Fig. 2). Similar ESI-MS spectra, showing the same
pattern of masses with substantially lower intensity, were
also obtained after 5-h sample incubation (data not shown).
This observation is in good agreement with our previous
time-dependent ESI-MS studies of the interaction of Pt(II)
complexes with human Zn7MT-2 [18].
Since the sum of the molecular masses of three zinc atoms
(196.11 g mol-1) is, considering the accuracy of the
method, very close to the molecular mass of one platinum
atom (195.09 g mol-1), the mass spectra were simulta-
neously recorded also at pH * 3 (Fig. 2a, b). Under these
conditions Zn(II), but not Pt(II) is released from the protein.
The deconvoluted ESI-MS spectrum of PtMT-3 complexes
with cisplatin obtained at pH * 3 reveals mass peaks of
7,118.6, 7,311.8, and 7,505.0 Da, which we assigned to the
MT-3 species containing one, two and three Pt(II) bound to
the protein, respectively (Fig. 2a). The ESI-MS spectrum of
the protein species formed with transplatin shows mass
peaks of 7,152.8, 7,380.5, and 7,607.0 Da. The increased
mass differences of Dm = 34.2, 68.7, and 98.0 Da for one,
two, and three Pt(II) bound are interpreted as being due to the
presence of two NH3 ligand per Pt(II), i.e., [Pt(NH3)2]MT-3,
[Pt(NH3)2]2MT-3, and [Pt(NH3)2]3MT-3 (Fig. 2b). Thus,
transplatin preserves its ammine ligands in complex with
MT-3. A comparison of the relative intensities of the mass
peaks at low pH reveals that the PtMT-3 complexes con-
taining one and two Pt(II) are mainly formed (Table 1).
The ESI-MS spectra obtained at pH * 7 were more
heterogeneous (Fig. 2c, d). In addition to the species of the
PtxZn7-xMT-3 (x = 1 - 3) type, a minor population of
PtxZn8-xMT-3 (x = 1 - 4) complexes was also formed
(Table 1). The formation of similar complexes with cis-
platin and transplatin was also seen in our previous studies
of Zn7MT-2 [18].
Kinetics of cisplatin and transplatin binding to thiols
of Zn7MT-3
The reactivity of cisplatin and transplatin toward the
cysteines of Zn7MT-3 was also investigated. As the plati-
num-to-MT ratio of 2 was applied in our studies, the pseudo-
first-order conditions cannot be fulfilled. Therefore, to allow
the comparison of the apparent initial rates of the reactions
involving cisplatin and transplatin, the experimental condi-
tions were kept identical. The formation of Pt–S bonds in
MT-3 with time was followed by absorption spectroscopy for
120 h to allow almost complete reaction. The results
obtained were normalized per Pt–S bond using the extinction
coefficient of 2,680 M-1 cm-1 at 285 nm [18].
The kinetic traces of the reaction of Zn7MT-3 with
2 mol equiv of cisplatin or transplatin show a biphasic




spectrometry spectra of Zn7MT-
3 upon the reaction with 2 mol
equiv of a, c cisplatin or b, d
transplatin in 10 mM N-(2-
hydroxyethyl)piperazine-N0-
ethanesulfonic acid (HEPES)/
NaOH pH 7.4, 100 mM NaClO4
for 120 h at 37 C. The masses
of the observed species are
given in Table 1. Prior to
analysis, samples were rapidly
diluted in a, b 50:50:0.2 (v/v/v)
CH3CN/H2O/HOAc (final
pH * 3) and in c, d 50:50 (v/v)
CH3CN/H2O (final pH * 7)
Table 1 Nano electrospray ionization mass spectrometry characterization of the products of the reaction between human Zn7MT-3 and 2 mol
equiv of cisplatin or transplatin at pH * 3 and pH * 7
Pt(II) compound pH * 3a pH * 7b
mexp
c (Da) mcalc




d (Da) Cation(s) in
complex with
MT-3
Cisplatin 6,926.3e 6,927.0 – 7,369.7f 7,370.8 Zn7
7,118.6 7,120.0 Pt 7,498.4 7,500.4 Pt Zn6
7,563.2 7,565.8 PtZn7
7,311.8 7,313.0 Pt2 7,629.2 7,630.0 Pt2Zn5
7,692.1 7,695.4 Pt2Zn6
7,505.0 7,506.0 Pt3 7,758.5 7,759.6 Pt3Zn4
7,952.0 7,954.6 Pt4Zn4
Transplatin 6,926.0e 6,927.0 – 7,370.0f 7,370.8 Zn7
7,152.8 7,154.1 [Pt(NH3)2] 7,532.9 7,534.5 [Pt(NH3)2]Zn6
7,380.5 7,381.2 [Pt(NH3)2]2 7,694.9 7,698.2 [Pt(NH3)2]2Zn5
7,761.5 7,763.6 [Pt(NH3)2]2Zn6
7,607.0 7,608.3 [Pt(NH3)2]3 7,864.1 7,861.9 [Pt(NH3)2]3Zn4
The experimental mass differences of up to 4 Da originate from an unpredictable protonation state of the protein at pH * 7
MT-3 metallothionein-3
a Samples were diluted in 50:50:0.2 CH3CN/H2O/HOAc prior to analysis
b Samples were diluted in 50:50 CH3CN/H2O prior to analysis
c Mass peaks obtained in nano electrospray ionization mass spectrometry experiments
d Calculated mass for the complexes of MT-3 with the cations indicated
e Mass obtained for apo-MT-3 in the control experiment; calculated: 6,927.0 Da
f Mass obtained for Zn7MT-3 in the control experiment; calculated: 7,370.8 Da
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profile characterized by a fast initial phase followed by a
slow second phase (Fig. 3a). The atomic absorption data
revealed that the final products of the reaction were com-
plexes with an overall stoichiometry of Pt2Zn5MT-3. In
these species up to approximately seven Pt–S bonds were
formed with cisplatin and approximately 3.5 Pt–S bonds
with transplatin. The higher number of Pt–S bonds formed
with cisplatin suggests that both ammine ligands were
replaced, resulting in a Pt(CysS)4 coordination. In contrast,
the presence of nearly 3.5 Pt–S bonds with transplatin
suggests that a Pt(NH3)2(CysS)2 species is formed. These
results are in agreement with the ESI-MS data presented
above. From the initial slopes of the kinetic traces, the
apparent initial rates kobs were derived and compared
(Fig. 3b). The value of 22.6 9 10-4 min-1 obtained for
the reaction of MT-3 with transplatin is higher than that
determined for cisplatin (kobs = 20.2 9 10
-4 min-1).
Thus, the reaction of both Pt(II) compounds with Zn7MT-3
is about twice as fast as with Zn7MT-2 [18].
Kinetics of cisplatin and transplatin binding
to Zn7MT-3
To investigate the rates of cisplatin and transplatin reaction
with Zn7MT-3 and, for comparison also with Zn7MT-2, we
determined free Pt(II) concentrations in the reaction mix-
ture as a function of time under identical experimental
conditions. The proteins were anaerobically incubated with
2 mol equiv of Pt(II) compounds in 10 mM HEPES/NaOH
pH 7.4, 100 mM NaClO4 at 37 C for up to 120 h. At
different time intervals, aliquots of the incubation mixture
were applied to Microcon YM-3 concentrators (molecular
mass cutoff 3 kDa) and the low molecular mass compo-
nents were separated. The concentration of free Pt(II)
present in the filtrate was determined by atomic absorption.
The amount of cisplatin and transplatin bound to Zn7MT-2/
Zn7MT-3 was obtained by subtracting the free Pt(II) con-
centration from the initial Pt(II) concentration. These val-
ues, normalized per protein concentration, are shown in
Fig. 4.
The kinetics presented in Fig. 4 show a biphasic profile
of Pt(II) binding to Zn7MT-3. A comparison of the rapid
initial kinetic phases of the reaction showed that transplatin
reacts with Zn7MT-3 about 1.6 times faster than cisplatin.
After 5-h incubation, a slow binding phase sets in with only
minor concentrations of free Pt(II) compounds after 120-h
incubation. Specifically, from the 2 mol equiv of cisplatin
and transplatin initially added to Zn7MT-3 about 1.98 mol
equiv was bound to the protein. Compared with Zn7MT-3,
Zn7MT-2 reacts with both cisplatin and transplatin on
average about 1.5 times slower during the first 5 h of
reaction (Fig. 4).
Fig. 3 a Kinetics of the binding of 20 lM cisplatin (black lines) and
transplatin (red lines) to cysteine thiolates of 10 lM human Zn7MT-3
(solid lines) and Zn7MT-2 (dotted lines) in 10 mM HEPES/NaOH
pH 7.4, 100 mM NaClO4 at 37 C. Complex formation with
time was monitored through absorption changes at 285 nm. The
absorption traces were normalized to the number of Pt–S bonds
(e285 nm = 2,680 M
-1 cm-1) [18]. b Comparison of the initial
apparent reaction velocities kobs of the cisplatin or transplatin binding
to Zn7MT-2 and Zn7MT-3. The experiments were performed in
triplicate
Fig. 4 Binding of 20 lM cisplatin (black lines) or transplatin (red
lines) to 10 lM Zn7MT-3 (solid lines) or Zn7MT-2 (dotted lines) in
10 mM HEPES (pH 7.4), 100 mM NaClO4, 37 C. The concentration
of bound Pt(II) was obtained by subtracting the free Pt(II) concen-
tration from the initial Pt(II) concentration added to the protein.
Values were normalized to the number of Pt(II) bound to MT-2/MT-3
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Kinetics of Zn(II) release from Zn7MT-3 upon cisplatin
and transplatin binding
The release of Zn(II) upon Pt(II) binding to Zn7MTs is a
direct consequence of the competition between these
metals for cysteine thiolates. The kinetics of Zn(II)
release was examined using the conditions described for
the reaction of cisplatin and transplatin with cysteine
thiolates and in the presence of the Zn(II)-chelating dye
zincon. The 1:1 Zn(II)–zincon complex formed, which is
characterized by an absorption maximum at 620 nm
(e620 nm = 23,200 M
-1 cm-1) [40, 46], was used to
monitor Zn(II) release. Prior to these experiments, the
absence of a complex between zincon and Pt(II) was
established. The results show that around 1.8 mol equiv
of Zn(II) was released from Zn7MT-3 after 120-h incu-
bation with 2 mol equiv of cisplatin and transplatin
(Fig. 5a). This indicates that Pt(II) binding leads to dis-
placement of the corresponding number of mole equiva-
lents of Zn(II) from the protein. As judged from the initial
slopes of the fast reaction phase, transplatin with k
ZnðIIÞ
obs of
54.3 9 10-4 min-1 releases Zn(II) from Zn7MT-3 more
rapidly than cisplatin (k
ZnðIIÞ
obs of 32.2 9 10
-4 min-1).
Moreover, the apparent rates of release of Zn(II) from
Zn7MT-3 are about twice as fast as those from Zn7MT-2
(Fig. 5b). A comparison of kobs for the Pt–S bond for-
mation (Fig. 3b) and Zn(II) release (Fig. 5b) reveals that
the Zn(II) release from Zn7MT-3 and Zn7MT-2 is roughly
twice as fast. This likely reflects the strong labilization of
Zn(II) in the cluster structure induced by the breaking of
even a single Zn–S bond. Although in all kinetic studies a
simple hyperbolic dependence was obtained, the reactions
are more complex and follow higher-order kinetics. Evi-
dence comes from the ESI-MS data in which the forma-
tion of different products was seen (Fig. 2).
113Cd NMR characterization of Pt1
113Cd6MT-3
To reveal whether the a-domain or the b-domain of MT-3
is preferentially reacting with cisplatin, we applied 113Cd
NMR spectroscopy. Previously, a close similarity between
the structures of Zn(II)- and Cd(II)-containing metallo-
forms of M7MT-2 was demonstrated [7]. Prior to NMR
measurements, the additional ESI-MS experiments estab-
lished that in the reaction of Cd7MT-3 with 1 mol equiv of
cisplatin heterogeneous PtxCd7-xMT-3 (x = 1 - 3) com-
plexes lacking ammine ligands, seen also with Pt,ZnMT-3,
were formed (data not shown). For 113Cd NMR measure-
ments 113Cd7MT-3 was incubated with 1 mol equiv of
cisplatin in 10 mM HEPES/NaOH pH 7.4, 100 mM
NaClO4 for 120 h. The Pt1
113Cd6MT-3 sample was then
concentrated to about 3 mM and brought into 15 mM
potassium phosphate/sodium phosphate buffer pH 7.3. The
113Cd NMR spectra of Pt1
113Cd6MT-3 and
113Cd7MT-3 are
shown in Fig. 6.
Fig. 5 a Time-dependent release of Zn(II) from 10 lM Zn7MT-3
(solid lines) and Zn7MT-2 (dotted lines) in 10 mM HEPES/NaOH pH
7.4, 100 mM NaClO4, 100 lM zincon at 37 C upon reaction with
20 lM cisplatin (black lines) or transplatin (red lines). The absorption
change with time was followed was followed at 620 nm. Values were
normalized to the number of Zn(II) released per MT. b Comparison of
the initial apparent reaction velocities k
ZnðIIÞ
obs of Zn(II) release from
human Zn7MT-2, and Zn7MT-3 upon reaction with cisplatin and
transplatin. The experiments were performed in triplicate
Fig. 6 113C NMR (110.9 MHz) spectra of a 2.7 mM 113Cd7MT-3
and b 3 mM Pt1
113Cd6MT-3 in 15 mM potassium phosphate/sodium
phosphate buffer pH 7.3 at 50 C. I, V, VI, and VII correspond to the
resonances of the four-metal cluster in the a-domain, and II, III, and
IV correspond to the resonances of the three-metal cluster in the
b-domain [47, 51]
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The 113Cd NMR spectrum of 113Cd7MT-3 presented in
Fig. 6a compares well with that published. As previously
shown, the strong 113Cd resonances I, V, VI, and VII
originate from the Cd4 cluster and the weak resonances II,
III, and IV originate from the Cd3 cluster [47, 48]. The
characteristic features of this spectrum are a large
apparent line width of all resonances (150–350 Hz), the
absence of homonuclear 113Cd–113Cd couplings, and a
markedly reduced and temperature-independent intensity
(20%) of the resonances of the Cd3 cluster. These features
have been interpreted in terms of dynamic processes
acting on two different NMR time scales: fast exchange
processes among conformational cluster substates occur-
ring in both clusters and additional slow exchange pro-
cesses among configurational cluster substates in the Cd3
cluster [48]. The latter exchange processes allowed only
the structure of the a-domain of 113Cd7MT-3 to be
determined by NMR [47].
In the spectrum of Pt1
113Cd6MT-3, the three-metal-
cluster resonances are virtually absent (Fig. 6). The per-
turbation of the four-metal-cluster resonances by Pt(II)
binding was only minor. This was characterized by a
broadening of the 113Cd resonance VII and a small low-
field shift of the 113Cd resonance VI from 622 to 623 ppm,
resulting in its overlap with resonance V (Table 2).
This suggests that Pt(II) is preferentially bound to the
more dynamic three-metal cluster. Furthermore, no other
113Cd resonances were detected between 900 and 350 ppm.
The monomeric nature of the Pt1
113Cd6MT-3 sample after
NMR measurements (72 h) was confirmed by analytical
gel filtration in which the presence of about 10–15% of
dimers was detected.
Discussion
The present study provides insights into the reaction of
human Zn7MT-3 with cisplatin and transplatin and the
products formed. The fate of the Pt(II) complexes in
the cells is kinetically controlled and will depend on the
accessibility of cysteine thiolates for electrophilic attack. In
mammalian MTs both metal–thiolate clusters are buried in
the protein structure. When compared with the structures of
the Zn7MT-1/Zn7MT–2 isoforms, the structure of Zn7MT-
3 is more flexible and both metal–thiolate clusters show
reduced metal affinity. These structural properties are
responsible for the higher reactivity of nucleophilic sulf-
hydryl groups in Zn7MT-3 with electrophiles such as 5,5
0-
dithiobis(2-nitrobenzoic acid) [31]. In this regard, the
three-metal cluster in the b-domain has been shown to be
more reactive than the four-metal cluster in the a-domain.
In our 113Cd NMR studies of Pt1
113Cd6MT-3, a similar
preferential reactivity of the Cd3 cluster with cisplatin was
also seen. The virtual absence of the 113Cd resonances of
the Pt(II)-modified Cd3 cluster in the b-domain presumably
reflects a low population of (Pt,Cd)3 complexes with
varying Pt(II) distributions. This conclusion is supported
by ESI-MS analysis of the product of the reaction of
Cd7MT-3 with 1 mol equiv of cisplatin, showing the for-
mation of complexes with platinum-to-MT ratios between
1 and 3. The results obtained differ from the results of the
similar 111Cd NMR studies of rabbit 111Cd7MT-2 where a
cooperative cisplatin binding to the three-metal cluster was
reported [49]. A number of studies showed that both pro-
tein domains in MT-3 interact with each other [50, 51].
Thus, a small perturbation of the Cd4-cluster resonances,
including a broadening of the cadmium VII resonance and
a small low-field shift of the cadmium VI resonance, most
likely originates from the changes in the cross-talk between
both protein domains brought about by Pt(II) binding to the
b-domain.
The characterization of the final products of the reaction
of Zn7MT-3 with 2 mol equiv of cisplatin or transplatin
resulted in a species with overall stoichiometry of
Pt2Zn5MT-3. In these species an average of seven Pt–S
bonds were formed with cisplatin and 3.5 Pt–S bonds with
transplatin. These results and the ESI-MS data indicate that
whereas in the reaction of Zn7MT-3 with cisplatin both
carrier and leaving ligands are lost, the carrier NH3 ligands
in transplatin were retained. The trans-effect labilization of
the carrier NH3 ligands in cisplatin trans to CysS accounts
for the generation of Pt(II)(SCys)4 complexes in
Pt2Zn5MT-3. The kinetic profiles of cisplatin and transpl-
atin binding to Zn7MT-3 reveal that about 1.7 mol equiv of
both Pt(II) compounds is bound to MT-3 already after 5 h.
In marked contrast, at the same time point only about half
of the total Pt–S bonds developed and 1 mol equiv of
Table 2 Effect of 113Cd7MT-3 platination on the chemical shifts and












I 675 1a 675 1a
II 661 0.49 661 –
III 649 0.51 649 –
IV 646 0.49 646 –
V 623 0.91 623 1.93
VI 621 0.86
VII 591 0.93 590 0.97
The 110.9-MHz 113Cd NMR spectra were recorded in
15 mM potassium phosphate/sodium phosphate buffer, pH 7.3 at
50 C
The numbers are relative to the integrated intensity of peak I
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Zn(II) was released. These results suggest that the binding
of Pt(II) complexes to the three-metal cluster in the b-
domain is a complex process, involving at least two sub-
sequent kinetic phases. This process could be interpreted as
initial binding of Pt(II) complexes to a reduced number of
thiolate groups (one or two). The subsequent saturation of
Pt(II) coordination sites by additional thiolate ligands
would then introduce substantial changes in the domain
structure accompanied by the release of the second mole
equivalent of Zn(II). Furthermore, as MT-3 contains 11
carboxylate donor ligands, representing a kinetically
attractive first protein coordinating site for cisplatin and
transplatin at pH 7.4, their possible involvement in the
initial binding step cannot be ruled out. In recent studies of
the binding of cisplatin to cellular DNA-binding proteins
similar platinum coordination sites have been identified
[52].
While the expression of the MT-1/MT-2 isoforms is
induced by toxic Cd(II) and Pt(II), the MT-3 expression is
unresponsive to these inducers. The exposure to these
metal ions results in their scavenging in the cytosol by
Zn7MTs and Zn(II) release. As the expression of MT-1/
MT-2 is regulated by zinc responsive transcription factor 1
(MTF-1), the released Zn(II), through activation of this
factor, leads to overexpression of MT-1/MT-2 [53, 54].
Activated MTF-1 also regulates the expression of other
proteins such as c-glutamylcysteine synthetase, zinc
transporter 1, and a-fetoprotein. The enzyme c-glutamyl-
cysteine synthetase is involved in the biosynthesis of GSH,
another sulfur-containing compound involved in the Pt(II)
resistance. As MTF-1 is not involved in the regulation of
MT-3 expression, the induction of this MT isoform by free
Zn(II) will not take place [55]. However, in recent studies
the MT-3 gene was identified as hypoxia-inducible in
several human tissues [56–58]. Therefore, we suggest that
overexpression of MT-3 observed in several cancers is a
result of the hypoxic conditions, due to insufficient vas-
cularization of the fast-proliferating tissue.
The MT-3 isoform has an increasing significance as a
diagnostic marker of bladder [28] and esophageal [27]
cancers and its presence in these and several other cancers
tightly correlates with the poor chemotherapy outcome
[25, 26, 59]. The degree of MT-based acquired resistance
to Pt(II) drugs may depend on the specific expression
pattern of MT isoforms. The data presented suggest that in
frequent situations of the overexpression of several MT
isoforms in the cancer tissues [17], the reaction of
administered Pt(II) drugs with MT-3 would be kinetically
preferred. The released Zn(II) in this process and its
binding to MTF-1 would then result in the upregulation of
the MT-1/MT-2 expression.
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